In conclusion, our study demonstrates that GCGR mAb not only ameliorates hyperglycaemia but also increases functional beta cell mass in mouse models of type 2 diabetes, and that these effects are at least partly mediated via liver-derived FGF21. This evidence concerns the gene GCGR and Hyperglycemia.